Dolutegravir and Ertugliflozin Interaction
Drug interaction information between Dolutegravir and Ertugliflozin.
Dolutegravir and Ertugliflozin have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Dolutegravir and Ertugliflozin. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Dolutegravir blocks the kidneys from removing metformin from the body, which causes metformin levels to rise and increases the risk of side effects.
What To Do
Your doctor should carefully consider the risks and benefits of using these two medications at the same time.
FDA Label Information
Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risks of concomitant use.
Dolutegravir Also Interacts With
- Dofetilide major
- Empagliflozin moderate
- Empagliflozin/Linagliptin moderate
- Linagliptin moderate
- Metformin/Empagliflozin moderate
Ertugliflozin Also Interacts With
- Metformin moderate
- Topiramate moderate
- Ranolazine moderate
- Cimetidine moderate
- Zonisamide moderate
Frequently Asked Questions
Can I take Dolutegravir and Ertugliflozin together?
This is a moderate interaction. Your doctor should carefully consider the risks and benefits of using these two medications at the same time.
How serious is the interaction between Dolutegravir and Ertugliflozin?
This interaction is classified as "moderate" severity by the FDA. Moderate interactions may worsen your condition or change how your medications work.
Why do Dolutegravir and Ertugliflozin interact?
Dolutegravir blocks the kidneys from removing metformin from the body, which causes metformin levels to rise and increases the risk of side effects.
Understanding the Dolutegravir and Ertugliflozin Interaction
FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Dolutegravir belongs to the Integrase Strand Transfer Inhibitor class and Ertugliflozin belongs to the SGLT2 Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Dolutegravir blocks the kidneys from removing metformin from the body, which causes metformin levels to rise and increases the risk of side effects. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Dolutegravir has 28 total documented interactions on file in this dataset, and Ertugliflozin has 8. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor should carefully consider the risks and benefits of using these two medications at the same time. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Dolutegravir or Ertugliflozin based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.